Comparative study of localised intradermal microinjection of tranexamic acid and oral tranexamic acid for the treatment of melasma
Keywords:Melasma, Tranexamic acid, Microinjection
Background: Melasma is an acquired hypermelanosis affecting the sun- exposed areas of the skin, most commonly the face and neck. Different treatment modalities have been utilized in different studies with varying, not so satisfactory outcomes. The aim of the study was to compare the efficacy of localized intradermal microinjection of tranexamic acid with oral tranexamic acid in melasma patients.
Methods: It is a prospective comparative study. All patients enrolled in the study were divided into 2 groups - twenty in each treatment group. In group A, patients were given intradermal injections of tranexamic acid (4 mg/ml) once at three week intervals (0, 3, 6, 9, 12 weeks) for 12 weeks. Group B patients were given oral tranexamic acid 250 mg twice a day for 12 weeks. Following parameters were evaluated before and after 12 weeks of treatment: a) digital photographs b) MASI score c) patient subjective assessment d) dermoscopic photographs. Software (SPSS, version 16.0 statistical packages) was used.
Results: Clinical efficacy of the treatment in 2 different groups showed higher efficacy with intradermal microinjection (35.6%) compare to oral tranexamic acid (21.7%). Patient's subjective assessment showed good improvement in 63.15% of cases in group A, whereas in group B 27.8% of cases showed good improvement.
Conclusions: Intralesional localized microinjection of tranexamic acid is a promising new therapeutic modality for the treatment of resistant melasma.
Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatol Online J. 2014;5:426-35.
Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol. 2006;55:1048-65.
Bentley-Phillips B, Bayles MA.Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation Afr Med J. 1975;49:1391-5.
Hurley ME, Guervara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138:1578-82.
Li YH, Chen JZ, Wei HC, Wu Y, Liu M, Xu YY, et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg. 2008;34:693-700.
Ando H, Matsui MS, Ichihashi M. Quasi- drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. Int J Mol Sci. 2010;11:2566-75.
Karn D, Kc S, Amatya A, Razouria EA, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J (KUMJ). 2012;10:40-3.
Calapai G, Gangemi S, Mannucci C, Miniullo PL, Casciaro M, Calapai F. Systematic review of tranexamic acid adverse reactions. J Pharmacovigil. 2015;3:1-7.
Nijor T. Treatment of melasma with tranexamic acid. Clin Res. 1979;13:3129-31.
Malathi M, Thappa DM. Systemic skin whitening/lightening agents: What is the evidence? Indian J Dermatol Venereol Leprol. 2013;79:842-6.
Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: A Preliminary Clinical Trial Dermatol Surg. 2006;32:626-31.
Maeda K, Tomita Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte- conditioned medium. J Health Sci. 2007;53(4):389-96.
Li D, Shi Y, Li M, Liu J, Feng X. Tranexamic acid can treat ultraviolet radiation - induced pigmentation in guinea pigs. Eur J Dermatol. 2010;20:289-92.
Elfar NN, El Maghraby GM. Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: A comparative study. J Clin Exp Dermatol Res. 2015;6:1-7.
Aamir S, Naseem R. Oral tranexamic acid in treatment of melasma in Pakistani population: A pilot study. J Pak Assoc Dermatol. 2014;24:198-203.
Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36:964-70.